- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
NorthStrive Biosciences Expands Licensing Deal with MOA Life Plus for Muscle-Preserving Treatments
The amended agreement aims to align development timelines for NorthStrive's dual myostatin assets EL-32 and EL-22 targeting muscle preservation alongside GLP-1 weight loss therapies.
Mar. 27, 2026 at 10:11pm
Got story updates? Submit your updates here. ›
NorthStrive Biosciences, a subsidiary of PMGC Holdings, has announced a third amendment to its existing licensing agreement with Korean biotech company MOA Life Plus [KOSDAQ: 142760]. The amendment updates the timing and key development milestones for NorthStrive's EL-32 and EL-22 human clinical programs, which focus on preserving muscle mass in combination with GLP-1 weight loss treatments.
Why it matters
The amended agreement reinforces NorthStrive's commitment to disciplined development planning as it progresses its portfolio of aesthetic and weight management medicines. Preserving muscle during weight loss is a key challenge, and NorthStrive's dual myostatin assets aim to address this issue by working alongside popular GLP-1 therapies.
The details
The amendment updates the timing and milestones for the clinical development of NorthStrive's EL-32 and EL-22 programs, which are focused on preserving muscle mass in patients undergoing weight loss treatments that utilize GLP-1 receptor agonists. NorthStrive believes the changes align the schedule with the parties' research, development, and regulatory expectations.
- NorthStrive Biosciences and MOA Life Plus first partnered in 2024 for the EL-32 and EL-22 assets.
- This is the third amendment to the original licensing agreement between the two companies.
The players
NorthStrive Biosciences Inc.
A biopharmaceutical company focused on developing and acquiring cutting-edge aesthetic medicines, including treatments targeting muscle preservation. NorthStrive Biosciences is a wholly owned subsidiary of PMGC Holdings Inc.
MOA Life Plus Co., Ltd.
A Korean biotechnology company focused on the research, development, and commercialization of innovative therapeutic and wellness technologies. MOA partners globally to advance scientific innovation across human and animal health applications.
PMGC Holdings Inc.
A diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries.
What’s next
The amended agreement aligns the development timelines for NorthStrive's EL-32 and EL-22 programs with the parties' research, development, and regulatory expectations. As NorthStrive continues to progress these muscle-preserving assets, further updates on clinical milestones and regulatory filings are anticipated.
The takeaway
NorthStrive Biosciences' expanded licensing deal with MOA Life Plus underscores the growing importance of preserving muscle mass during weight loss treatments. By pairing its myostatin-targeting assets with popular GLP-1 therapies, NorthStrive aims to address a key challenge in the obesity and metabolic health space.
